Search

Objective: To investigate the clinical characteristics and pregnancy outcomes of women with uterine rupture. Methods: This retrospective study analyzed clinical data from 43 women who experienced uterine rupture during delivery at the Affiliated Obstetrics and Gynaecology Hospital of Nanjing Medical University from December 2016 to December 2022. The participants were divided into scarred and non-scarred uterus groups based on their histories of uterine surgery. Additionally, the delivery outcomes of 20 women who underwent vaginal trial of labor was analyzed. Results: Of the 43 cases, 33 women involved a scarred uterus group, and 10 women involved a non-scarred uterus group. The non-scarred uterus group exhibited significantly higher intraoperative blood loss ≥ 1 000 mL（P ＜ 0.001）and cumulative blood loss ≥1 000 mL（P=0.003）compared to the scarred uterus group, along with a higher rate of blood transfusion（P=0.012). Among those 43 cases, 23 women underwent expected cesarean sections, while 20 opted for vaginal trial delivery. In the vaginal trial delivery patients, there was a notable increase in complete uterine ruptures（P=0.044）and rate of blood transfusion（P ＜ 0.001）in the group with uterine rupture detected during delivery（7 cases), compared with the group with uterine rupture detected after delivery（13 cases). Furthermore, the group with uterine rupture detected during delivery showed a higher incidence of abnormal amniotic fluid and fetal heart rate changes. Although these differences did not reach statistical significance（P ＞ 0.05), they still warrant significant clinical attention. Conclusion: Non-scarred uterus exhibit more bleeding when rupture occurs. Patients undergoing vaginal trial delivery who experience postpartum uterine rupture face more severe complications. It is essential to closely monitor amniotic fluid, fetal heart rate, and vital signs before and after delivery to promptly detect uterine rupture and reduce adverse pregnancy outcomes. [ABSTRACT FROM AUTHOR]

Copyright of Journal of New Medicine is the property of Sun Yat Sen University and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective To investigate the impacts of circular RNA lipoprotein receptor 6 （circLRP6） on cisplatin （CDDP） resistance to esophageal squamous cell carcinoma （ESCC） and its relevant potential molecular mechanism. Methods CDDP‐resistant cell lines of KYSE30（ KYSE30/CDDP‐R） were established and divided into a control group, si‐NC group, si‐circLRP6 group, si‐circLRP6 plus anti‐NC group, and si‐circLRP6 plus anti‐miR‐ 125a‐5p group. The expression levels of circLRP6, miR‐125a‐5p and myeloid leukemia‐1 （MCL‐1） in tissues/cells were detected by RT‐qPCR and Western blot. CCK‐8 assay was applied to detect the CDDP sensitivity of KYSE30/CDDP‐R cells, so was flow cytometry to detect apoptosis. Results mRNA levels of circLRP6 and MCL‐1 were increased, while level of miR‐125a‐5p was decreased in ESCC cancer tissues/cells and CDDP‐resistant cancer tissues （P < 0.001）. CircLRP6 silencing was able to up‐regulate miR‐125a‐5p, inhibit the expression of MCL‐1, enhance the sensitivity of CDDP‐resistant ESCC cells to CDDP in vitro and in vivo, and promote the apoptosis of CDDP‐resistant ESCC cells. Inhibition of miR‐125a‐5p weakened the effects of circLRP6 silencing on CDDP resistance and apoptosis in CDDP‐resistant ESCC cells （P < 0.05）. circLRP6 could target and negatively regulate the expression of miR‐125a‐5p, and MCL‐1 was the target of miR‐125a‐5p. Conclusion CircLRP6 silencing may enhance the sensitivity of CDDP‐resistant ESCC cells to CDDP through the miR‐125a‐5p/MCL‐1 axis. [ABSTRACT FROM AUTHOR]